News & Updates

Show Multimedia Only

Managing CTD-ILD progression with antifibrotics: Clinical insights and guideline updates

10 Mar 2026 by

Up to 40 percent of patients with connective tissue disease–associated interstitial lung disease (CTD-ILD) develop progressive pulmonary fibrosis, which requires more intensive management beyond immunosuppressants to control the decline in lung function. At the International Conference of Chinese Rheumatologists 2025, Professor Rohit Aggarwal from the Division of Rheumatology, University of Pittsburgh, US, discussed the therapeutic role of nintedanib as an antifibrotic in CTD-ILD management and shared recent updates from international guidelines.

Managing CTD-ILD progression with antifibrotics: Clinical insights and guideline updates

10 Mar 2026

HZ and stroke risk: Implications for zoster vaccination

10 Mar 2026 by

In an interview with MIMS Doctor, Dr Kay-Cheong Teo, Specialist in Neurology, and Dr Anthony Tam, Specialist in Infectious Disease, both from the University of Hong Kong, discussed the intricate herpes zoster (HZ)–stroke relationship. They also highlighted how recombinant zoster vaccine (RZV), with its high efficacy and favourable safety profile, can play a significant role in preventing HZ, mitigating varicella zoster virus (VZV)–related sequelae such as debilitating post-herpetic neuralgia (PHN), and potentially reducing stroke risk, as demonstrated by recent cohort studies.

HZ and stroke risk: Implications for zoster vaccination

10 Mar 2026

Growth hormone replacement therapy for GHD: Early diagnosis and treatment initiation improves response

09 Mar 2026 by

Diagnosis of growth hormone deficiency (GHD) is important and should be made early as it is easily treatable with GH replacement (somatropin) therapy. In an interview with MIMS Doctor, Dr Wai-Man But gave an overview of the diagnosis and management of GHD, and shared a patient case who achieved growth normalization with early initiation of GH treatment.

Growth hormone replacement therapy for GHD: Early diagnosis and treatment initiation improves response

09 Mar 2026

Metronomic oral vinorelbine in frail and elderly patients with advanced NSCLC

27 Feb 2026 by

Metronomic chemotherapy has emerged as an effective treatment option with low toxicity for elderly and unfit patients. In an interview with MIMS Oncology, Dr Ashley Cheng, Specialist in Clinical Oncology in private practice in Hong Kong, discussed use of metronomic oral vinorelbine (m-OV) in frail patients with advanced non-small-cell lung cancer (NSCLC) and highlighted its advantages, including convenience and favourable tolerability.

Metronomic oral vinorelbine in frail and elderly patients with advanced NSCLC

27 Feb 2026

[Infographics] DESTINY-Gastric04: Superior OS with 2L T-DXd in HER2+ metastatic GC/GEJA

25 Feb 2026

As a confirmatory trial building on DESTINY-Gastric02, the phase III DESTINY-Gastric04 trial showed OS benefits with T-DXd vs standard 2L treatment with ramucirumab plus paclitaxel in patients with HER2+ metastatic GC/GEJA, including the Asia subgroup.

[Infographics] DESTINY-Gastric04: Superior OS with 2L T-DXd in HER2+ metastatic GC/GEJA

25 Feb 2026

Glucocorticoid-free control in a patient with relapsing EGPA within 6 months of treatment with an anti–IL-5

20 Feb 2026 by

A 75-year-old male nonsmoker was diagnosed with adult-onset asthma at 54 years old in 2004, with blood eosinophil counts (BEC) rising from 1,500 cells/ μL in 2004 to 1,800 cells/μL in 2006, while serum immunoglobulin E (IgE) remained normal. He tested negative for antineutrophil cytoplasmic antibody (ANCA) and stool ova/cysts.

Glucocorticoid-free control in a patient with relapsing EGPA within 6 months of treatment with an anti–IL-5

20 Feb 2026

Optimizing perioperative management in UKA: Role of ropivacaine in local infiltration analgesia

20 Feb 2026

Unicompartmental knee arthroplasty (UKA) is a minimally invasive procedure that is well suited to early mobilization and can therefore be done as day surgery, while local infiltration analgesia (LIA) is an important part of multimodal pain management that supports enhanced recovery after surgery (ERAS). Various practical strategies can aid perioperative management of UKA, and choosing a suitable local anaesthetic, such as ropivacaine, for LIA is crucial for optimizing postoperative outcomes, according to insights presented at a local symposium.

Optimizing perioperative management in UKA: Role of ropivacaine in local infiltration analgesia

20 Feb 2026

Evolving role of lenvatinib in management of unresectable HCC

20 Feb 2026 by

At an industry-sponsored symposium during the International Liver Cancer Association (ILCA) 2025 Annual Conference, Dr Krittiya Korphaisarn of Mahidol University, Bangkok, Thailand, reviewed systemic therapy for advanced hepatocellular carcinoma (HCC), focusing on lenvatinib as a second-line (2L) option following immunotherapy (IO). Professor Joseph Llovet of the University of Barcelona, Barcelona, Spain, and Tisch Cancer Institute at Mount Sinai, New York, US, and Professor Masatoshi Kudo of the Kindai University, Osaka, Japan, discussed the integration of systemic and locoregional treatments for intermediate HCC to optimize outcomes through multidisciplinary care.

Evolving role of lenvatinib in management of unresectable HCC

20 Feb 2026

JAK1/2 inhibitor provides rapid and durable disease control in a patient with myelofibrosis

13 Feb 2026 by

A 67-year-old man was diagnosed with polycythaemia vera (PV) in 2005. Over the next several years, he received various cytoreductive agents, including anagrelide, pegylated interferon (IFN) and hydroxyurea.

JAK1/2 inhibitor provides rapid and durable disease control in a patient with myelofibrosis

13 Feb 2026

Add-on sotatercept in a young patient with congenital heart disease–associated PAH

12 Feb 2026 by

A 19-year-old female university student with congenital heart disease–associated pulmonary arterial hypertension (PAH-CHD), who was on triple therapy and used home and portable oxygen, was referred to us for adult CHD management in July 2025. She had been referred earlier for lung transplantation due to severe PAH.

Add-on sotatercept in a young patient with congenital heart disease–associated PAH

12 Feb 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Managing CTD-ILD progression with antifibrotics: Clinical insights and guideline updates

Managing CTD-ILD progression with antifibrotics: Clinical insights and guideline updates

HZ and stroke risk: Implications for zoster vaccination

HZ and stroke risk: Implications for zoster vaccination

Growth hormone replacement therapy for GHD: Early diagnosis and treatment initiation improves response

Growth hormone replacement therapy for GHD: Early diagnosis and treatment initiation improves response

Metronomic oral vinorelbine in frail and elderly patients with advanced NSCLC

Metronomic oral vinorelbine in frail and elderly patients with advanced NSCLC

[Infographics] DESTINY-Gastric04: Superior OS with 2L T-DXd in HER2+ metastatic GC/GEJA

[Infographics] DESTINY-Gastric04: Superior OS with 2L T-DXd in HER2+ metastatic GC/GEJA

Glucocorticoid-free control in a patient with relapsing EGPA within 6 months of treatment with an anti–IL-5

Glucocorticoid-free control in a patient with relapsing EGPA within 6 months of treatment with an anti–IL-5

Optimizing perioperative management in UKA: Role of ropivacaine in local infiltration analgesia

Optimizing perioperative management in UKA: Role of ropivacaine in local infiltration analgesia

Evolving role of lenvatinib in management of unresectable HCC

Evolving role of lenvatinib in management of unresectable HCC

JAK1/2 inhibitor provides rapid and durable disease control in a patient with myelofibrosis

JAK1/2 inhibitor provides rapid and durable disease control in a patient with myelofibrosis

Add-on sotatercept in a young patient with congenital heart disease–associated PAH

Add-on sotatercept in a young patient with congenital heart disease–associated PAH